Background: TOUR™ is a multicenter study designed to characterize the real-world population characteristics and clinical outcomes associated with telavancin (TLV) use through retrospective medical chart review. Telavancin is a lipoglycopeptide antibacterial active against gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). In the US, TLV is approved for hospital-acquired (HABP) and ventilator-associated [...]